EDMONTON, Oct. 24 /CNW/ - BioMS Medical Corp (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced it has
received approval in all of the Baltic States (Lithuania, Estonia, and Latvia)
from their respective agencies to begin enrolling patients into its ongoing
pivotal phase II/III trial of MBP8298, a proprietary synthetic peptide for the
treatment of secondary progressive multiple sclerosis (SPMS).
